Sumita Ray

Insider · Chief Legal Compliance Officer · CUE

Sumita Ray files insider transactions with the SEC as a chief legal compliance officer of Cue Biopharma (CUE). We hold 1 disclosed purchase or sale filed since 24 June 2013, 1 of them in the last 90 days.

Files forCUE
Disclosed buys and sells1 in all, 1 in the last 90 days
Last disclosure17 August 2026

Positions held

6 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 9 July 2026 — 13 August 2026Chief Legal Compliance Officer · Cue Biopharma (CUE)7 Form 4 lines · source: SEC Form 4
Filed 16 June 2021 — 10 June 2026Director · Biomea Fusion (BMEA)7 Form 4 lines · source: SEC Form 4
Filed 1 November 2023 — 1 November 2023Chief Legal, Comp & Admin Off · Vaxxinity (VAXX)1 Form 4 line · source: SEC Form 4
Filed 8 January 2023 — 18 January 2023Chief Legal and Admin Officer · Instil Bio (TIL)2 Form 4 lines · source: SEC Form 4
Filed 29 September 2017 — 25 January 2022Officer · Calithera Biosciences (CALA)10 Form 4 lines · source: SEC Form 4
Filed 24 June 2013 — 31 October 2013Chief Compliance Officer · Pharmacyclics (PCYC)4 Form 4 lines · source: SEC Form 4

Everything they disclosed

31 entries, newest first — one per disclosure report, one per Form 4 line

exercised options over 18,196 shares of Cue BiopharmaSEC Form 417 August 2026Common Stock · traded 13 August 2026 · filed 17 August 2026
▼ sold on the open market 2,383 shares of Cue BiopharmaSEC Form 417 August 2026Common Stock · traded 13 August 2026 · filed 17 August 2026
▼ sold on the open market 6,442 shares of Cue BiopharmaSEC Form 417 August 2026Common Stock · traded 13 August 2026 · filed 17 August 2026
▼ sold on the open market 4 shares of Cue BiopharmaSEC Form 417 August 2026Common Stock · traded 13 August 2026 · filed 17 August 2026
exercised options over 18,196 shares of Cue Biopharma (a derivative holding)SEC Form 417 August 2026Common Stock · traded 13 August 2026 · filed 17 August 2026
was granted 54,589 shares of Cue BiopharmaSEC Form 410 July 2026Common Stock · traded 9 July 2026 · filed 10 July 2026
was granted 54,589 shares of Cue Biopharma (a derivative holding)SEC Form 410 July 2026Common Stock · traded 9 July 2026 · filed 10 July 2026
was granted 196,299 shares of Biomea Fusion (a derivative holding)SEC Form 412 June 2026Stock Option (Right to Buy) · traded 10 June 2026 · filed 12 June 2026
was granted 91,970 shares of Biomea Fusion (a derivative holding)SEC Form 413 June 2025Stock Option (Right to Buy) · traded 11 June 2025 · filed 13 June 2025
was granted 51,025 shares of Biomea Fusion (a derivative holding)SEC Form 413 June 2024Stock Option (Right to Buy) · traded 12 June 2024 · filed 13 June 2024
was granted 425,000 shares of Vaxxinity (a derivative holding)SEC Form 429 April 2024Employee Stock option (right to buy) · traded 1 November 2023 · filed 29 April 2024
was granted 6,989 shares of Biomea Fusion (a derivative holding)SEC Form 416 June 2023Stock Option (Right to Buy) · traded 14 June 2023 · filed 16 June 2023
was granted 415,000 shares of Instil Bio (a derivative holding)SEC Form 420 January 2023Employee Stock Option (right to buy) · traded 8 January 2023 · filed 20 January 2023
was granted 50,000 shares of Instil Bio (a derivative holding)SEC Form 420 January 2023Employee Stock Option (right to buy) · traded 18 January 2023 · filed 20 January 2023
was granted 23,867 shares of Biomea Fusion (a derivative holding)SEC Form 424 June 2022Stock Option (Right to Buy) · traded 22 June 2022 · filed 24 June 2022
was granted 21,461 shares of Biomea Fusion (a derivative holding)SEC Form 47 March 2022Stock Option (Right to Buy) · traded 3 March 2022 · filed 7 March 2022
was granted 165,000 shares of Calithera Biosciences (a derivative holding)SEC Form 427 January 2022Employee Stock Option (Right to Buy) · traded 25 January 2022 · filed 27 January 2022
was granted 12,000 shares of Calithera BiosciencesSEC Form 49 November 2021Common Stock · traded 5 November 2021 · filed 9 November 2021
was granted 36,000 shares of Calithera BiosciencesSEC Form 429 October 2021Common Stock · traded 27 October 2021 · filed 29 October 2021
was granted 17,724 shares of Biomea Fusion (a derivative holding)SEC Form 421 June 2021Stock Option (Right to Buy) · traded 16 June 2021 · filed 21 June 2021
was granted 30,000 shares of Calithera BiosciencesSEC Form 422 January 2021Common Stock · traded 20 January 2021 · filed 22 January 2021
was granted 12,000 shares of Calithera BiosciencesSEC Form 422 January 2021Common Stock · traded 20 January 2021 · filed 22 January 2021
was granted 125,000 shares of Calithera Biosciences (a derivative holding)SEC Form 422 January 2021Employee Stock Option (Right to Buy) · traded 20 January 2021 · filed 22 January 2021
was granted 110,000 shares of Calithera Biosciences (a derivative holding)SEC Form 422 January 2020Stock Option (Right to Buy) · traded 17 January 2020 · filed 22 January 2020
was granted 90,000 shares of Calithera Biosciences (a derivative holding)SEC Form 414 January 2019Stock Option (Right to Buy) · traded 10 January 2019 · filed 14 January 2019
was granted 25,000 shares of Calithera Biosciences (a derivative holding)SEC Form 411 October 2018Stock Option (Right to Buy) · traded 9 October 2018 · filed 11 October 2018
was granted 75,000 shares of Calithera Biosciences (a derivative holding)SEC Form 43 October 2017Stock Option (Right to Buy) · traded 29 September 2017 · filed 3 October 2017
acquired or disposed of, other 112 shares of PharmacyclicsSEC Form 46 November 2013Common Stock · traded 31 October 2013 · filed 6 November 2013
was granted 10,000 shares of Pharmacyclics (a derivative holding)SEC Form 415 July 2013Stock Option (Right to Buy) · traded 24 June 2013 · filed 15 July 2013
was granted 30,000 shares of Pharmacyclics (a derivative holding)SEC Form 410 July 2013Stocvk Option (Right to Buy) · traded 9 July 2013 · filed 10 July 2013
was granted 10,000 shares of Pharmacyclics (a derivative holding)SEC Form 424 June 2013Stock Option (Right to Buy) · traded 24 June 2013 · filed 24 June 2013

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.